» Publications

SCI-SSCI or SCI Expanded Articles

  • Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer? Köstek O, Hacıoğlu MB, Sakin A, Demir T, Sarı M, Ozkul O, Araz M, Doğan AF, Demircan NC, Uzunoğlu S, Çiçin İ, Erdoğan B.Cancer Chemother Pharmacol. 2019 Jan;83(1):115-122. doi: 10.1007/s00280-018-3713-6. Epub 2018 Oct 29. PMID: 30374523 (January 2019)
  • Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer. Köstek O, Yılmaz E, Hacıoğlu MB, Demircan NC, Gökyer A, Uzunoğlu S, Tunçbilek N, Çiçin İ, Erdoğan B. Cancer Chemother Pharmacol. 2019 Apr;83(4):735-742. doi: 10.1007/s00280-019-03779-5. Epub 2019 Jan 24 (January 2019)
  • Value of MRI apparent diffusion coefficient for assessment of response to sorafenib in hepatocellular carcinoma. Kostek O, Yilmaz E, Bekir Hacıoglu M, Erdogan B, Kodaz H, Turkmen Bekmez E, Hacibekiroglu I, Uzunoglu S, Tuncbilek N, Cicin I J BUON. 2018 Jul-Aug;23(4):979-984. (July 2018)
  • Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer even with brain metastasis. Muhammet Hacioglu B, Kostek O, Erdogan B, Uzunoglu S, Cicin I. J BUON. 2017 May-Jun;22(3):586-591. (May 2017)
  • Retrospective multicenter evaluation of patients diagnosed with mucosal melanoma: a study of Anatolian Society of Medical Oncology. Ercelep O, Topcu TO, Bayoglu IV, Ekinci AS, Koca S, Kavgaci H, Ozcelik M, Alacacioglu A, Uzunoglu S, Bozkurt O, Ulas A, Aksoy A, Taskoylu BY, Gumussay O, Yaman S, Uysal M, Aydin D, Gumus M. Tumour Biol. 2016 Sep;37(9):12033-12038. Epub 2016 May 12. (September 2016)
  • Retrospective multicenter evaluation of patients diagnosed with mucosal melanoma: a study of Anatolian Society of Medical Oncology. Ercelep O, Topcu TO, Bayoglu IV, Ekinci AS, Koca S, Kavgaci H, Ozcelik M, Alacacioglu A, Uzunoglu S, Bozkurt O, Ulas A, Aksoy A, Taskoylu BY, Gumussay O, Yaman S, Uysal M, Aydin D, Gumus M. Tumour Biol. 2016 Sep;37(9 (September 2016)
  • KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer. Kodaz H, Taştekin E, Erdoğan B, Hacıbekiroğlu İ, Tozkır H, Gürkan H, Türkmen E, Demirkan B, Uzunoğlu S, Çiçin İ. Balkan Med J. 2016 Jul;33(4):407-10 (Eylül 2016) (September 2016)
  • Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation. Erdogan B, Kodaz H, Karabulut S, Cinkaya A, Tozkir H, Tanriverdi O, Cabuk D, Hacioglu MB, Turkmen E, Hacibekiroglu I, Uzunoglu S, Cicin I. Bosn J Basic Med Sci. 2016 Jul 1. doi: 10.17305/bjbms.2016.1380. (Temmuz 2016) (July 2016)
  • Unknown primary adenocarcinomas: a single-center experience. Uzunoglu S, Erdogan B, Kodaz H, Cinkaya A, Turkmen E, Hacibekiroglu I, Sari A, Ozen A, Usta U, Cicin I. Bosn J Basic Med Sci. 2016 Jul 25. doi: 10.17305/bjbms.2016.1495. (Temmuz 2016) (July 2016)
  • Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.Turkmen E, Erdogan B, Kodaz H, Hacibekiroglu I, Onal Y, Uzunoglu S, Kilic N, Cicin I.Acta Gastroenterol Belg. 2016 Apr-Jun;79(2):211-5. (Haziran 2016) (June 2016)
  • Single-agent bevacizumab is an effective treatment in recurrent glioblastoma. Hacibekiroglu I, Kodaz H, Erdogan B, Turkmen E, Ozcelik M, Esenkaya A, Saygi HM, Uzunoglu S, Cicin I (February 2015)
  • Kodaz H, Hacibekiroglu I, Turkmen E, Erdogan B, Elpen C, Uzunoglu S, Cicin I. Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer. (February 2015)
  • Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors. Kodaz H, Hacibekiroglu I, Erdogan B, Turkmen E, Tozkir H, Albayrak D, Uzunoglu S, Cicin I Mol Clin Oncol. 2015 Jan;3(1):179-184 (January 2015)
  • Impact of bevacizumab on survival outcomes in primary tumor resected metastatic colorectal cancer. Kodaz H, Erdogan B, Hacibekiroglu I, Turkmen E, Gurkan H, Albayrak D, Tastekin E, Uzunoglu S, Cicin I (January 2015)
  • Hacibekiroglu I, Kodaz H, Erdogan B, Turkmen E, Esenkaya A, Uzunoglu S, Cicin I Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance Status.Asian Pac J Cancer Prev. 2015;16(6):2355-9
  • Incidence of contrast-induced nephropathy in hospitalised patients with cancer. Cicin I, Erdogan B, Gulsen E, Uzunoglu S, Sut N, Turkmen E, Kodaz H, Ustundag S. Eur Radiol. 2014 Jan;24(1):184-90 (January 2014)
  • A small cell carcinoma in the testis associated with testicular teratoma. Türkmen E, Erdoğan B, Kodaz H, Uzunoğlu S Balkan Med J. 2014 Jun;31(2):191-2. (January 2014)
  • Carnitine or dimethyl sulfoxide, or both, for the treatment of anthracycline extravasation in rats. Uzunoglu S, Cosar R, Cicin I, Ibis K, Demiralay E, Benlier E, Erdogan B, Kandulu H, Ozen A, Altaner S. J Plast Surg Hand Surg. 2013 Oct;47(5):339-43 (October 2013)
  • Performance status is an important prognostic factor in second line treatment of pancreaticobiliary adenocarcinoma. Erdogan B, Turkmen E, Uzunoglu S, Tanriverdi O, Cicin I. Hepatogastroenterology. 2013 Sep;60(126):1479-83. (September 2013)
  • Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer. Uzunoglu S, Aybatlı A, Kaplan PB, Cicin I, Sut N, Sayın C, Varol F. Med Oncol. 2013 Mar;30(1):447. (March 2013)
  • Efficient and safe application of a FOLFIRI/bevacizumab combination to a patient with locally advanced rectal cancer and severe chronic renal failure. Cicin I, Karagol H, Uzunoglu S, Uygun K. Onkologie. 2007 Feb;30(1-2): (February 2007)
  • Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma - A retrospective single-center study Cicin, I (Cicin, Irfan); Karagol, H (Karagol, Hakan); Uzunoglu, S (Uzunoglu, Sernaz); Uygun, K (Uygun, Kazim); Usta, U (Usta, Ufuk); Kocak, Z (Kocak, Zafer); Caloglu, M (Caloglu, Murat); Saynak, M (Saynak, Mert); Tokatli, F (Tokatli, Fusun); Uzal, C (Uzal, Cem)
    13
    ATIF

International Articles

  • Assessment of prognostic factors in epithelial ovarian cancer, Eurasian Journal of Medicine and Oncology, 1, 2017 (October 2017)
  • Frequency of RAS Mutations (KRAS, NRAS, HRAS) in Human Solid Cancer (Ağustos 2017) (August 2017)
  • K-RAS and N-RAS mutations in testicular germ cell tumors.Hacioglu BM, Kodaz H, Erdogan B, Cinkaya A, Tastekin E, Hacibekiroglu I, Turkmen E, Kostek O, Genc E, Uzunoglu S, Cicin I.Bosn J Basic Med Sci. 2017 Apr 20. doi: 10.17305/bjbms.2017. (April 2017)
  • Clinical Features of the Patient with Multiple Primary Tumors: Single Center Experience, Gokyer A, Kostek O, Hacioglu MB, Erdogan B, Kodaz H, Turkmen E, Hacibekiroglu I, Uzunoglu S, Cicin I.Northern Clinics of Istanbul, vol. 4, no. 1, pp. 43-41, 1, 2017 (January 2017)

International Conferences and Symposiums

  • 7th International Gastrointestinal Cancers Conference Date: 12/16/2017 Time: 08:30-08:45 Session XI: Management of Small Intestinal Cancers Chairs: Özlem Ata, Murat Dinçer • General overview of small intestinal cancers o Sernaz Uzunoğlu • Medical Treatment of intestinal adenocarcinomas o Orhan Önder Eren (December 2017)
  • 6th International Gastroistestinal Cancer Conference,2-4 december,2016 General overview of small intestinal cancers (December 2016)

National Articles

  • Systemic Chemotherapy in Ovarian Germ Cell and Stromal Cancers,,Sernaz UZUNOĞLU, İrfan ÇİÇİN, Türkiye Klinikleri J Med Oncol- Special topics 2016;9(1):41-51 (September 2016)
  • How Many Lines of Chemotherapy Should Be Applied in Metastatic Non-Small Cell Lung Cancer?Sernaz UZUNOĞLU, İrfan ÇİÇİN, Türkiye Klinikleri J Med Oncol- Special topics 2016;9(4):56-64 (April 2016)
  • Kastrasyona Dirençli Prostat Kanserinde Kemoterapi ve Hedefe Yönelik Tedavi Türkiye klinikleri Üroloji Özel sayı; 2014;7(4):108-117
  • Treatment of Primary Tumors Relapsed or Refractory Glial and Targeted Therapies S UZUNOĞLU, İ ÇİÇİN Turkiye Klinikleri J Med Oncol-Special Topics 2013;6(1):43-9

National Conferences and Symposiums

  • Klinik Onkolojide Tartışmalı Konular ve Kök Hücre Araştırmalarında Etik Yaklaşımlar- Muğla Multidisipliner Onkolojik Araştırmalar Sempozyumu (MORE 2017) Tarih: 14.EKİM2017-CUMARTESİ Saat: 14.50-15.10 Süre:20 DAKİKA Oturum: SİSTEMİK TEDAVİDE TARTIŞMALI OLGULARDA ALGORİTMİK YAKLAŞIMLAR-5 Oturum Başkanları: Dr. Ahmet Alacacıoğlu, Dr. Erdem Göker Konu: Metastatik Her2 (+) meme kanserinde sıralı tedaviler algoritması Konuşmacı: Sernaz Uzunoğlu (October 2017)
  • Eskişehir Onkoloji günleri V. OTURUM 20.05.2017 - Cumartesi Saat : 13:30 -14.00 Oturum Başkanı : Nilüfer Güler Konuşmacı : Hormon reseptörü pozitif meme kanseri (adjuvan ve metastatik seri tedavisinde yenilikler Sernaz Uzunoğlu (May 2017)
  • 22. Ulusal kanser kongresi (Kurs) 19.Nisan 2017.......17:00-17:30 B-RAF İnhibitörlerinin Yan Etkileri ve Yönetimleri Sernaz Uzunoğlu (April 2017)
  • 4. Karadeniz meme Kongresi TARİH: 30 Mart 2017, Perşembe KONFERANS SAATİ: 14:50-15:20 KONFERANS: Adjuvan Endokrin Tedavide Son Durum MODERATÖR: Önder Berk KONUŞMACI: Sernaz Uzunoğlu (March 2017)
  • Ege hematoloji Onkloloji Kongresi 18-20 mart 2016 Çeşme KHDAK'de farmakogenomi, Dr.Sernaz Uzunoğlu (March 2016)
  • 11. Ulusal Tıbbi Onkoloji Kongresinde Sözel bildiri tartışmacısı (September 2014)
  • Trakya İç Hastalıkları Günleri 30 mayıs-1 haziran 2014 31 mayıs cumartesi Kanserde Ağrı tedavisi (May 2014)
  • Hedef Kanser 2014 Biyobenzerlerin getireceği tehdit.Özgün Antikorlara Direnç konulu sempozyumda tartşmacı (April 2014)
  • Ege Hematoloji Onkoloji Sempozyumu 27-29 Mart Metastatik mide kanserinde sistemik tedavi (09:45-10.30)(28 mart Cuma) (March 2014)

National Books and Book Chapters

  • GEBELİKTE KANSER TEDAVİSİ BÖLÜM 13 GEBELİKTE TİROİD KANSERLERİ Doç. Dr. Sernaz Uzunoğu 1. GİRİŞ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109 2. GEBELİKTE TİROİD HORMON FİZYOLOJİSİ VE TİROİDEKTOMİZE GEBE KADINLARDA ANNE VE FETÜSE BAŞLICA ETKİLERİ. . . . . . . . . . . . . . . . . . . . . . . 109 3. GEBELİKTE SAPTANAN TİROİD NODÜLLERİNE YAKLAŞIM . . 110 4. GEBELİK VE TİROİD KANSER PROGNOZU . . . . . . . . . . . . . 111 5. TİROİD KANSERİNİN GEBELİKTE TAKİP VE TEDAVİSİ . . . . . 112 6. GEBELİKTE TİROİD KANSERLERİNİN SİSTEMİK TEDAVİSİ . . 114 7. DİFFERANSİYE TİROİD KANSERİ TEDAVİSİ SONRASI GEBELİK VE NÜKS RİSKİ . . . . . . . . . . . . . . . . . . . . . . . . 114 8. SONUÇ . . . .115 (April 2017)